利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.034 秒)

    HER2 DIAGNOSTIC METHODS
    2.
    发明申请
    HER2 DIAGNOSTIC METHODS 有权
    HER2诊断方法

    公开(公告)号：US20090191559A1

    公开(公告)日：2009-07-30

    申请号：US12340436

    申请日：2008-12-19

    申请人： Weidong Huang ,  Jeff Sperinde ,  Michael Bates ,  Colombe Chappey

    发明人： Weidong Huang ,  Jeff Sperinde ,  Michael Bates ,  Colombe Chappey

    IPC分类号： C12Q1/68 ,  C12Q1/02 ,  G01N33/574

    CPC分类号： G01N33/574 ,  G01N33/57415 ,  G01N2800/52

    摘要： In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.

    摘要翻译： 在某些方面，本发明提供用于确定Her-2阳性癌症是否可能对Her2-作用剂的治疗有反应和/或是否具有Her-2阳性癌症的患者可能具有慢的疾病的方法 进步。 在其它方面，本发明涉及用于确定具有Her-2阳性癌症的受试者是否不太可能响应除了Her2作用剂之外的至少一种化学治疗剂的治疗和/或患者是否具有 一个Her-2阳性的癌症很可能有一个快速的疾病进展。

    Compositions and methods for determining the replication capacity of a pathogenic virus
    3.
    发明申请
    Compositions and methods for determining the replication capacity of a pathogenic virus 审中-公开
    用于确定致病病毒的复制能力的组合物和方法

    公开(公告)号：US20050214750A1

    公开(公告)日：2005-09-29

    申请号：US11052741

    申请日：2005-02-04

    申请人： Neil Parkin ,  Colombe Chappey ,  Michael Bates

    发明人： Neil Parkin ,  Colombe Chappey ,  Michael Bates

    IPC分类号： C12Q1/68 ,  C12Q1/70 ,  G01N33/48 ,  G01N33/50 ,  G01N33/569 ,  G06F19/00

    CPC分类号： G01N33/56988 ,  C12Q1/703

    摘要： This invention relates to methods for predicting replication capacity of a virus based on genotype and identifying targets for antiviral therapy by identifying mutations associated with altered replication capacity. The methods are useful, for example, for identifying previously unknown interactions among viral molecules or between viral molecules and host cell molecules that are essential to viral infection and/or replication. By identifying such interactions, novel targets for antiviral therapy can be identified. In another aspect, the invention provides a method for determining that an HIV has an altered replication capacity. In certain embodiments, the method comprises detecting a mutation in a codon of gag that is selected from the group consisting of 437, 439, 441, 442, 454, 478, 479, and 484. In certain embodiments, the mutation is selected from the group consisting of I437L, P439S, E454V, P478L, and I479K In certain embodiments, the mutation is in a codon of gag that is selected from the group consisting of 418, 456, 456, 453, 418, 483, 481, 465, 429, 484, 481, 483, 484, 465, 454, 442, 479, 418, 479, and 486.

    摘要翻译： 本发明涉及用于基于基因型预测病毒的复制能力的方法，并且通过鉴定与改变的复制能力相关的突变来鉴定抗病毒治疗的靶标。 该方法例如用于鉴定病毒分子之间或病毒分子与病毒感染和/或复制必需的宿主细胞分子之间的先前未知的相互作用是有用的。 通过鉴定这种相互作用，可以鉴定抗病毒治疗的新靶点。 另一方面，本发明提供了确定HIV具有改变的复制能力的方法。 在某些实施方案中，该方法包括检测gag密码子中的突变，其选自437,439,441,442,454,478,479和484.在某些实施方案中，突变选自 由I437L，P439S，E454V，P478L和I479K组成的组。在某些实施方案中，突变是gag的密码子，其选自418,456,465,453,418,483,481,465,429 ，484,481,483,484,465,454,442,479,418,479和486。

    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
    4.
    发明授权
    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors 有权
    用于确定致病病毒对蛋白酶抑制剂的敏感性的组合物和方法

    公开(公告)号：US07993824B2

    公开(公告)日：2011-08-09

    申请号：US10612603

    申请日：2003-07-01

    申请人： Colombe Chappey ,  Christos J. Petropoulos ,  Neil T. Parkin

    发明人： Colombe Chappey ,  Christos J. Petropoulos ,  Neil T. Parkin

    IPC分类号： C12Q1/70 ,  C12Q1/68 ,  G01N33/00

    CPC分类号： C12Q1/703

    摘要： The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.

    摘要翻译： 本发明提供了一种基于通过表型临床切片指导的配对表型和基因型数据的综合分析来开发用于确定抗病毒药物有效性的算法的方法。 在一个方面，算法允许给患者提供有效的治疗。 它有助于预测受感染的个体是否会对抗病毒化合物进行治疗反应，从而允许设计有效的治疗方案，而不会对患者造成不必要的副作用。 此外，通过避免无效药物的管理，节省了大量的时间和金钱。

    Method for determining reduced susceptibility of HIV to protease inhibitor treatment
    7.
    发明申请
    Method for determining reduced susceptibility of HIV to protease inhibitor treatment 审中-公开
    确定HIV对蛋白酶抑制剂治疗的易感性降低的方法

    公开(公告)号：US20050214749A1

    公开(公告)日：2005-09-29

    申请号：US11051812

    申请日：2005-02-04

    申请人： Colombe Chappey ,  Christos Petropoulos ,  Neil Parkin

    发明人： Colombe Chappey ,  Christos Petropoulos ,  Neil Parkin

    IPC分类号： C12Q1/68 ,  C12Q1/70 ,  G06F19/00

    CPC分类号： C12Q1/703 ,  C12Q1/683 ,  G16B30/00

    摘要： The present invention provides methods and devices for predicting whether a HIV variant will be resistant to an antiviral drug based on the variant's genotype. In one aspect, methods are provided comprising determining whether a combination of protease inhibitor resistance mutations meet certain conditions, as disclosed herein, thereby assessing the effectiveness of ritonavir-boosted indinavir therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV resistance are provided.

    摘要翻译： 本发明提供了用于基于变体的基因型来预测HIV变体是否能够抗抗病毒药物的方法和装置。 在一个方面，提供了方法，其包括确定蛋白酶抑制剂抗性突变的组合是否满足本文所公开的某些条件，从而评估利托那韦加强的茚地那韦治疗在HIV感染受试者中的有效性。 提供了包括确定HIV抗性的计算机实施方法。

    METHOD FOR DETERMINING RESISTANCE OF HIV TO PROTEASE INHIBITOR TREATMENT
    8.
    发明申请
    METHOD FOR DETERMINING RESISTANCE OF HIV TO PROTEASE INHIBITOR TREATMENT 审中-公开
    用于确定HIV对蛋白酶抑制剂治疗的抗性的方法

    公开(公告)号：US20100070184A1

    公开(公告)日：2010-03-18

    申请号：US12160693

    申请日：2007-01-19

    申请人： Neil T. Parkin ,  Colombe Chappey

    发明人： Neil T. Parkin ,  Colombe Chappey

    IPC分类号： C12Q1/70 ,  G06F19/00

    CPC分类号： C12Q1/703 ,  G16B20/00 ,  G16B40/00

    摘要： The present invention provides methods and devices for predicting whether an HIV-I is likely to have a reduced susceptibility to an antiviral drug based on the HIV-I's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with altered susceptibility to protease inhibitors are present, as disclosed herein, thereby assessing the effectiveness of tipranavir therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-I's altered susceptibility are provided.

    摘要翻译： 本发明提供了用于预测HIV-1基于HIV-1基因型是否可能对抗病毒药物的易感性降低的方法和装置。 一方面，本发明提供了如本文所公开的确定突变或与蛋白酶抑制剂的易感性相关的突变的组合是否存在的方法，从而评估了在HIV感染的受试者中替诺韦韦治疗的有效性。 提供了确定HIV-1改变易感性的计算机实施方法。

    Method for Determining Resistance of Hiv to Nucleoside Reverse Transcriptase Inhibitor Treatment
    9.
    发明申请
    Method for Determining Resistance of Hiv to Nucleoside Reverse Transcriptase Inhibitor Treatment 审中-公开
    用于确定核苷逆转录酶抑制剂治疗抗性的方法

    公开(公告)号：US20080293038A1

    公开(公告)日：2008-11-27

    申请号：US11915307

    申请日：2006-05-25

    申请人： Neil T. Parkin ,  Colombe Chappey ,  Jeannette Whitcomb

    发明人： Neil T. Parkin ,  Colombe Chappey ,  Jeannette Whitcomb

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/6883 ,  C12Q2600/156

    摘要： The present invention provides methods and devices for predicting whether an HIV-1 is resistant to an antiviral drug based on the HIV-1's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with NRTI resistance are present, as disclosed herein, thereby assessing the effectiveness of FTC therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-1 resistance are provided.

    摘要翻译： 本发明提供了用于预测HIV-1是否对基于HIV-1的基因型的抗病毒药具有抗性的方法和装置。 一方面，本发明提供了如本文所公开的确定是否存在与NRTI抗性相关的突变或突变的组合的方法，从而评估FTC治疗在HIV感染的受试者中的有效性。 提供了确定HIV-1抗性的计算机实施方法。

    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
    10.
    发明授权
    Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors 有权
    用于确定致病病毒对蛋白酶抑制剂的敏感性的组合物和方法

    公开(公告)号：US07384734B2

    公开(公告)日：2008-06-10

    申请号：US10367223

    申请日：2003-02-13

    申请人： Neil T. Parkin ,  Colombe Chappey ,  Christos J. Petropoulos

    发明人： Neil T. Parkin ,  Colombe Chappey ,  Christos J. Petropoulos

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/703 ,  C12Q2600/156

    摘要： The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.

    摘要翻译： 本发明提供了一种基于通过表型临床切片指导的成对表型和基因型数据的综合分析来开发用于确定抗病毒药物有效性的算法的方法。 在一个方面，算法允许给患者提供有效的治疗。 它有助于预测受感染的个体是否会对抗病毒化合物进行治疗反应，从而允许设计有效的治疗方案，而不会对患者造成不必要的副作用。 此外，通过避免无效药物的管理，节省了大量的时间和金钱。